The plant that never shipped a box wrong still can't get one across the border.

A container of finished devices sits in a bonded warehouse at the port of Long Beach, flagged the moment it hit customs because the manufacturer's plant in Gujarat is sitting on an FDA import alert nobody at the US distributor knew existed until this shipment.

Every future container from that plant will do the same thing until someone actually gets the plant off the alert, not just this one load released. The customs broker who cleared the paperwork has never touched an FDA petition. The distributor needs a different kind of firm, and needs it this week.

The border is already a search, separate from the factory floor

This practice runs on a different trigger than a domestic 483 or a stalled 510k. The problem shows up as a shipment that will not clear: an import alert placing an entire manufacturer or product line on automatic detention, a "detention without physical examination" notice on a specific entry, or a foreign manufacturer that never registered a US Agent and cannot get a straight answer from the agency about what is actually required before the first shipment.

None of this is about what happens inside the plant. It is about whether the product is even allowed to cross the line.

A domestic compliance consultant who has spent a career on inspections and quality systems is often the wrong person for this, and knows it. Getting a plant removed from an import alert is a documentation and petition exercise aimed at customs and an import division, not a quality-system remediation aimed at an investigator. The skill sets overlap on paper and diverge completely in practice.

Domestic 483 response and submission strategy are a different leaf entirely: see FDA compliance consulting. That page covers inspections and warning letters at a US-registered facility. This page covers whether a product gets past the border at all.

What a buyer is actually searching

The manufacturer or importer with a detained shipment types FDA import alert release, detention without physical examination consultant, DWPE removal, FDA import alert petition, almost always with a specific entry number or alert number already in hand. A manufacturer building US market entry from scratch searches differently: FDA US agent service, foreign facility registration, FSVP consultant for a food importer, prior notice FDA, focused on the foundational build rather than an active hold.

A generic "FDA consultant" or "import compliance" campaign misses both buyers, because most of the traffic it generates is either a customs question with no FDA component or a domestic quality-system question that belongs on a different page entirely.

Objections we hear

We already have a customs broker. A broker clears paperwork and classifies tariffs. A broker does not build the compliance record or file the petition that gets a manufacturer removed from an import alert, and most brokers say so directly when asked.

We already appointed a US Agent. A US Agent is a required point of contact for FDA correspondence, nothing more. The agent receives the import alert notice. Getting off the alert is a separate body of work the agent role does not include.

Isn't this the same as the 483 firm we already talked to? Not usually. Most domestic FDA consultants have never filed an import alert petition, because it runs through a different part of the agency and a different evidentiary standard than a quality-system remediation does.

A release is not the same as getting off the list

FDA does not physically inspect every shipment from a flagged manufacturer under an import alert. It automatically detains all of them, and a single successful petition to release one entry does nothing for the next container behind it. Removal from the alert itself usually requires the manufacturer to build a record, often five or more consecutive shipments cleared through private laboratory testing acceptable to the agency, before the automatic detention stops. A firm that treats one release as the finish line leaves the manufacturer back at the same wall on the next vessel.

Ready to grow your pipeline?

Share a few details and we'll follow up with exactly how this works for a firm like yours.

Leave blank

Name *

Firm / Company *

Email *

Phone

Send

What runs, and what we will not do

Google ads built around the specific search a manufacturer or importer actually types, an import alert release, a US Agent requirement, a facility registration, not one generic "FDA consultant" campaign competing for domestic inspection and submission queries it was never meant to win. Foundational web presence, so the click lands on a firm that reads as an import and border specialist, not a generalist compliance firm that happens to mention imports on one page.

LinkedIn placements aimed at customs, trade, and life-sciences lawyers who send this work once they already know which firm handles the border side rather than the inspection side, run as paid placements only, never InMail, connection-request sequences, or direct messages. We do not run that channel, and it is not part of this program under any name.

What we will not do: write into the detention. We do not build a solicitation list of foreign manufacturers or importers, and we do not mail, email, or call a company that has not searched or asked. We do not file the petition or manage the registration ourselves. We make the firm findable. The firm does the work.

Why a generalist agency gets this practice wrong

An agency selling "FDA consultant" or "import compliance" leads at scale cannot tell a manufacturer with a container sitting at the port apart from a domestic company responding to a warning letter, two entirely different regulatory processes that happen to share a regulator. They also rarely understand that a customs broker and an import-alert petition specialist are not interchangeable, which means a real share of the traffic they generate goes to a firm that cannot actually do the work.

This campaign is built for the buyer who already has a detained shipment, an import alert, or a market-entry deadline, not the team researching what FDA import compliance even means.

Referring counsel matter as much as the search itself

Customs and trade lawyers see import holds constantly but rarely file the FDA-side petition themselves, and a client asking for that work puts counsel in the position of naming a specialist fast, often with a container already accruing storage fees. That referral relationship deserves deliberate attention, not whichever firm happens to come up first.

The LinkedIn side of this program exists for that purpose: a small number of paid placements in front of the lawyers who send this work, built as material worth their time, not an ad asking for a meeting.

How this is billed

This is Visibility Program work, not the outbound program. You pay ad spend directly to the platforms, Google and, where it runs, LinkedIn. ROI Wire bills a retainer that scales with that spend, not a flat project fee and not a percentage of closed files.

A landing page may be included at no additional cost. A full website build is always quoted and billed separately. Copywriting, directory work, and the reputation surfaces a manufacturer or importer checks before trusting a firm with a held shipment sit under this track as the credibility layer that holds the traffic, not as a correspondence program running in parallel. Ads can be live in under a week. Approval on your side, the keywords, the spend, the page the click lands on, usually determines the timeline, not the platforms.

Who this fits, and who it does not

This fits firms that actually work import alerts, detention petitions, US Agent appointments, and facility registration for foreign manufacturers, with the capacity to move fast once a shipment is held. The lead worth the spend is a manufacturer or importer with a real detained shipment or a genuine market-entry timeline, not a company browsing what FDA import compliance means.

It does not fit a firm whose real business is domestic inspection response or submission strategy. That is FDA compliance consulting, which covers 483s, warning letters, and stalled submissions at a US-registered facility, and lives on its own page.